BEIJING (Reuters) – A COVID-19 vaccine developed by a unit of China’s Chongqing Zhifei Biological Products (Zhifei) showed a 81.76% efficacy rate against COVID-19 cases of any degree of severity in a late-stage trial, Zhifei said on Friday.
The efficacy readings came from a Phase III clinical trial that recruited 28,500 participants and recorded 221 cases by the time of analysis, Zhifei said in a filing.
(Reporting by Roxanne Liu and Ryan Woo; editing by Jason Neely)
